Navigation Links
NineSigma Engages AtriCure in the Ohio Third Frontier Open Innovation Incentive Program

CLEVELAND, Dec. 4, 2012 /PRNewswire/ -- NineSigma, Inc., of Cleveland, the leading innovation partner to organizations worldwide, announced today they will work with Cincinnati, OH-based AtriCure, Inc. under the new Ohio Third Frontier Open Innovation Incentive (OII) Program. In August, NineSigma was selected by the State of Ohio to help catalyze the growth of middle market companies, with revenues between $10 million and $1 billion, by accelerating their adoption of open innovation. The Ohio Third Frontier OII is aimed at fostering collaborative innovation that will lead to job creation within Ohio and build competitive advantage on the national and global level.  

AtriCure, Inc. is a growing medical device company with a strong presence in atrial fibrillation (AF). They are a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems. These systems are designed to create precise lesions, or scars, in heart tissue for the treatment of atrial fibrillation. AF is the most common irregular heartbeat and is characterized by palpitations, dizziness and shortness of breath.

"Atrial fibrillation affects more than 5.5 million people worldwide and carries with it a five-fold increased risk of stroke. We look forward to beginning our work with the team at AtriCure to help them find best-in-class partners and technologies globally that will advance their cardiac surgical solutions and ability to treat this pervasive condition," said Andy Zynga, CEO of NineSigma.

Open innovation involves "looking to the outside" for technologies, solutions, and ideas to accelerate the development of new products and increase speed to market. Through the Open Innovation Incentive, NineSigma will work closely with solution seekers to create custom networks of innovation providers to find viable solutions, filtering responses for their quality and fit. The State will assist solution seekers by funding a portion of the transactional costs of engaging an open innovation company.

About NineSigma

NineSigma connects organizations with external innovation resources to accelerate innovation in private, public and social sectors. The company provides open innovation services to organizations worldwide, including Kraft, Philips, Siemens, and Unilever, to solve immediate challenges, integrate new knowledge, fill product pipelines, and stay ahead of the competition. Named to the 2012 Inc. 5000 list of fastest-growing private U.S. companies, NineSigma's proprietary process has produced billions of dollars in value for its clients. NineSigma has the largest open global network of solution providers and an extensive database of existing solutions spanning numerous industries and technical disciplines. NineSigma's online innovation community, NineSights™, is the world's first open innovation social media destination, connecting innovators of all sizes with resources and relationships to drive growth. Learn more at and

Media Contact: 
Jackie Lucas, Warner Communications —, (978) 255-1159 

SOURCE NineSigma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NineSigma Partners with Scientists Without Borders to Find New Sustainable Packaging for Micronutrient Powders that Combat Malnutrition
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. WuXi PharmaTech Announces Third-Quarter 2011 Results
5. Interleukin Genetics Reports Third Quarter 2011 Financial Results
6. Spherix Announces Third Quarter Financial Results
7. Nile Therapeutics Reports 2011 Third Quarter Financial Results
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):